Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

IVF breakthrough? pill could replace daily shots

NCT ID NCT05954962

First seen Mar 29, 2026 · Last updated Jun 22, 2026 · Updated 14 times

Summary

This completed Phase 4 trial tested whether an oral progesterone pill (Seidigestan) can replace daily injections of ganirelix (Astarté) for preventing early ovulation during IVF. The study enrolled 150 healthy egg donors aged 18-33. If the pill works as well as the injections, it could simplify IVF by eliminating the need for painful daily shots.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IVF are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Instituto Bernabeu

    Elche, Alicante, 03206, Spain

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

micronized natural progesterone (Seidigestan) and ganirelix acetate (Astarté)

What this could lead to

If successful, this could show that taking a simple progesterone pill is as effective as daily injections for preventing early ovulation during IVF, making treatment easier for patients.

What could go wrong

This is a completed Phase 4 trial with 150 participants, so results are available but may not apply to all IVF patients. The study only included young, healthy egg donors, so findings may not generalize to older women or those with fertility issues.

Conditions

The condition(s) this trial relates to.

ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.